The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Beyond technology, regulations weigh heavily on the minds of pharma executives. Four out of 10 leaders believe regulatory ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

Lilly announced several changes to its executive leadership team. 1 These changes are mostly related to the company’s ...

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing ...

In an effort to combat the state’s shortage of primary care physicians, Blue Cross Blue Shield of Massachusetts is offering ...

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health ...

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

Kapil Raina, MD, Principal of Market Access at Herspiegel Consulting, talks about disconnects in the industry, how patients ...

The idea of creating a gray zone in the payer message is to take the onus off of having to heavily discount for equal access ...